T he innate immune responses serve as the body's first line of defense against invading pathogens. To be efficient in stopping subsequent microbial spread inside the body, the innate immune reactions must be spontaneous, fast and relatively non-specific. Thus, the innate immune system requires a preformed mechanism for identifying and eliminating microbes. It has long been proposed that innate immune effector cells possess sensors (cell surface receptors) that are capable of recognizing specific molecular structures unique to microbes. This forms the basis for the general theory of innate immune recognition proposed by the late Charles A. Janeway, Jr., who also predicted that the adaptive immune response is controlled by the more ancient innate immune system.
(1) The brilliant insights of Dr. Janeway revolutionized our understanding of the immune system and formed the conceptual framework of the workings of the innate immune responses and the links between innate and adaptive immunity. The announcement of 2011 Nobel Prize in Physiology or Medicine to 3 leading immunologists (Jules A. Hoffmann, Bruce A. Beutler, Ralph M. Steinman) in a way is a testimony to the great contributions made by Charles A. Janeway, Jr. (Figure) .
Identification of innate immune receptors for pathogen-associated molecular patterns
Professor Jules A. Hoffmann started his scientific career by working on the origins and roles of blood cells in the grasshopper, followed by biochemical studies of insect hormones. He finally focused on insect immunity, especially on the molecular and cellular aspects of the innate immune response of Drosophila.
Interested in understanding how the innate immune system senses the presence of microorganisms, Prof. Hoffmann and colleagues employed D. melanogaster (fruit fly) as a model organism and identified the Toll receptor as a sensor for fungal infection in 1996. (2) Toll was first identified to be important for the embryonic development of the fruit fly by Christiane Nusslein-Volhard, a 1995 Nobel laureate in Physiology or Medicine. (3) This finding opened an exciting new research avenue for the molecular mechanisms whereby innate immune cells recognize and distinguish "self" from "non-self" molecules. As in the fruit fly, humans have many Toll-like receptors (TLRs) which are now known to recognize a diverse array of pathogen-associated molecular patterns (PAMPs). (4) One of the best examples of the interaction of cognate PAMPs and TLRs is that of lipopolysaccharide (LPS, endotoxin) and TLR-4 ( Figure) , which was identified by Bruce A. Beutler. (5) An immunologist and geneticist, Beutler is best known for his pioneering work on inflammation and innate immunity. He was the first to isolate mouse tumor necrosis factor-α (TNF-α) and to establish its important role as the inflammatory mediator in LPSinduced shock. (6, 7) His interest in the mechanism by which LPS activates innate immune cells led him to use TNF-α secretion as an assay endpoint for identification of LPS receptors. Using positional cloning techniques, Beutler and colleagues successfully mapped and identified the genetic alteration encoded by the Lps locus in endotoxin-tolerant mice.
(5) The mutated gene allele turned out to be TLR-4. The finding of TLR-4 as the membrane-spanning component of the LPS receptor complex led to further understanding of signaling pathways and identification of many relevant adaptor molecules important for the production of pro-inflammatory cytokines.
Identification of dendritic cells that bridge innate and adaptive immune responses
In 1973 whilc working in a macrophage laboratory, Dr. Ralph Steinman discovered a tree-like cell type distinct from conventional macrophages and hence named dendritic cells (DCs), which had the unique ability to trap intact antigens and present them to lymphocytes. (8, 9) This novel finding eventually bridged the gap in knowledge between the innate and adaptive immune systems. Professor Steinman studied this cell population and even tried to combine DC experimental therapies to treat his own pancreatic cancer. DCs comprise less than 1% of human blood cells or cells in mice spleen and at that time it took him almost 5 years to purify enough DCs for research. Despite these difficulties, Dr. Steinman was able to demonstrate that DCs are 100 times more potent than bulk splenocytes in initiating the activation of quiescent lymphocytes. (10) He also demonstrated the existence of 2 functional stages of DCs, immature DCs which mainly capture and present antigens and mature DCs which co-stimulate activation of lymphocytes. (11, 12) In addition to the activation of T lymphocytes, Dr. Steinman's group found a role for DCs in controlling immune tolerance through DEC-205. The approach to generate antigen-specific T regulatory cells capable of preventing immune activation was also described recently. (13) Dr. Steinman believed that DCs had a very high potential for application in medical regimens. In his first experiments using DCs for medical treatment, he removed DCs from cancer patients, charged the cells with tumor antigens and put them back into the patients. This approach has been approved by the US Food and Drug Administration. (14) DC-based vaccines targeting infections diseases such as malaria, tuberculosis, and AIDS have also been tested. (15) Dr. Steinman performed experiments to demonstrate how DCs function to initiate clonal expansion of the adaptive immune system and regulation of antigenspecific immune responses. His studies on DCs are essential for understanding collaboration and regulation between the two main branches of the immune systems.
The findings by these three laureates have brought us new insights into immune responses to infectious agents and tumors. They have provided the bases for new ideas in the development of vaccines and cancer therapies, and control of autoimmune diseases. Most importantly, their work has greatly deepened our understanding of fundamental immunology and opened many avenues for future research.
